2. Immunology/Inflammation Metabolic Enzyme/Protease Anti-infection
  3. Toll-like Receptor (TLR) MMP HSV Antibiotic
  4. FSL-1 TFA

FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

FSL-1 TFA Chemical Structure

FSL-1 TFA Chemical Structure

Size Price Stock Quantity
100 μg USD 160 In-stock

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of FSL-1 TFA:

FSL-1 TFA Related Antibodies

Top Publications Citing Use of Products

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms
TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection[1]. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2].

IC50 & Target[1][2]

TLR2

 

HSV-2

 

TLR6

 

MMP-9

 

In Vitro

FSL-1 TFA significantly reduces HSV-2 replication in human vaginal epithelial cells (EC)[1].
FSL-1 TFA induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile[1].
FSL-1 TFA (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells[2].
FSL-1 TFA activates the MAP kinase/NF-κB signaling pathway[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

FSL-1 TFA Related Antibodies

Cell Viability Assay[1]

Cell Line: V11I, V12I or V19I immortalized human vaginal EC
Concentration: 6 μg or 0.1 μg
Incubation Time: Added at 24, 6 or just prior to HSV-2 inoculation (104pfu/well)
Result: The 6 μg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 μg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge.
In Vivo

FSL-1 TFA application significantly protectes against genital HSV-2 challenge in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Swiss-Webster mice (weighing 20-25 g)[1]
Dosage: 2 or 6 μg
Administration: Delivered vaginally using a positive displacement pipet, prior to or following viral challenge as specified for each experiment.
Result: The 2 μg does delivered 6 h prior to HSV-2 challenge increased the ID50 (260 pfu) and LD50 (660 pfu) by 10-fold compared to DPBS vehicle control.
The single 6 μg dose produced significantly improved outcomes compared to DPBS vehicle application.
Molecular Weight

1666.16 (free acid)

Formula

C84H140N14O18S.xC2HF3O2
Appearance

Solid

Color

White to off-white

Sequence Shortening

S-(2, 3-Bispalmitoyloxypropyl)-CGDPKHPKSF
Shipping

Shipping with dry ice.
Storage

-80°C
Solvent & Solubility
In Vitro: 

H2O : 50 mg/mL (Need ultrasonic)

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

FSL-1 TFA Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

FSL-1FSL1FSL 1Toll-like Receptor (TLR)MMPHSVAntibioticMatrix metalloproteinasesHerpes simplex virusInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
FSL-1 TFA
Cat. No.:
HY-P2036A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.